Advancing toward goal of ten or more potentially registrational trials running by the end of 2024: first patient dosed in Phase 3 clinical trial evaluating.
IDEXX Laboratories, Inc. (NASDAQ:IDXX) Q1 2024 Earnings Call Transcript May 1, 2024 IDEXX Laboratories, Inc. beats earnings expectations. Reported EPS is $2.81, expectations were $2.7. IDXX isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning and welcome to the […]
Payments and billing software maker Bill.com (NYSE:BILL) beat analysts' expectations in Q1 CY2024, with revenue up 18.5% year on year to $323 million. On top of that, next quarter's revenue guidance ($325 million at the midpoint) was surprisingly good and 3.3% above what analysts were expecting. It made a non-GAAP profit of $0.60 per share, improving from its profit of $0.50 per share in the same quarter last year.
Banco Santander, S.A. (NYSE:SAN) Q1 2024 Earnings Call Transcript April 30, 2024 Banco Santander, S.A. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Begoña Morenés: Good morning everybody and welcome to Banco Santander’s Conference Call to Discuss our Financial Results for […]